O'Brien Annual Conference on new Advances treating CML

[Guest guest]

O'Brien, MD: " I am going to talk about chronic myelogenous leukemia (CML)

today. If you were in the National Comprehensive Cancer Network (NCCN) CML

Guidelines presentation yesterday, there will be some overlap because I

presented some data to address the change in the guidelines, which mainly was

the addition of nilotinib now that that has Food and Drug Administration (FDA)

approval as another drug that we can use in patients who become resistant to

imatinib or are intolerant to imatinib. But some of it will be new or different

than what was presented yesterday.

" Of course, what has made CML the prototype for the development of targeted

therapy is the fact that you find the same chromosome abnormality in everybody

with the disease, and that is usually not true in most other diseases. The

Philadelphia chromosome (Ph) is the (9;22) translocation which forms the

messenger ribonucleic acid (RNA), which is then transcribed into an aberrant

protein that drives the disease. "

http://www.medscape.com/viewarticle/573165

FYI,

Lottie